Several years ago, multiple infectious outbreaks related to duodenoscopes used for endoscopic retrograde cholangiopancreatography (ERCP) were reported in medical journals and the news media. These drew significant attention to the issue of contaminated duodenoscopes, and endoscopes in general, and led to a variety of innovations in patient screening, endoscope reprocessing, and scope design. However, infections related to endoscopes are not a new phenomenon.1 In the 1970s and 80s, there were nearly 50 reports of Salmonella spp. infections linked to endoscopes.2 Over 200 cases of Pseudomonas infection (in straight-viewing devices and duodenoscopes) and several cases of Hepatitis B virus cross-infection were also reported…
Author: Praveen Suthrum
Results of a new study by researchers at Case Western Reserve University represent a step toward improving our understanding of Crohn’s disease and the factors that cause its intestinal inflammation. Crohn’s disease is a type of inflammatory bowel disease that can lead to chronic inflammation of the entire digestive tract. Symptoms include diarrhea, pain and cramping, fatigue, weight loss and more. There is no cure for Crohn’s disease, but patients can alleviate symptoms with current treatment options.
Despite a challenging regulatory framework, growth in PE investment in health care has been steadily outpacing the wider sector since 2009. In 2000, there were 191 PE health care deals, whereas by 2020 that number had risen to 2,360, the highest total on record. The lead investor from 2007 to 2020 was Amsterdam-based Alpinvest Partners, while the leading US domestic investor was Kohlberg Kravis Roberts in New York.
Gastroenterologists (GI) may soon gain a useful new tool for use in gathering both biopsies and diagnostic information when examining the gastrointestinal tract. Ongoing development of a new robotic device promises both capabilities using technology that will be of interest to GI pathologists and clinical laboratory scientists. Researchers at the University of Colorado Boulder’s Advanced Medical Technologies Laboratory (AMTL) have developed a capsule-sized robotic device called “Endoculus” which they believe could eventually replace traditional endoscopes used in colonoscopies and endoscopies.
NASHVILLE, Tenn., Jan. 11, 2022 /PRNewswire/ — One GI, a gastroenterology management services organization, has partnered with Great Lakes Gastroenterology (“GLG”) in the Cleveland, OH market. Headquartered in Nashville, Tennessee, One GI identifies and partners with leading gastroenterology practices that are seeking a strategic alliance to provide capital and management services to help foster growth, drive economies of scale, and deliver the highest quality care to patients.
NASHVILLE, Tenn., Jan. 13, 2022 /PRNewswire/ — One GI, a gastroenterology management services organization, has partnered with Digestive Health Associates (“DHA”) in the Terre Haute, IN market. Headquartered in Nashville, Tennessee, One GI identifies and partners with leading gastroenterology practices that are seeking a strategic alliance to provide capital and management services to help foster growth, drive economies of scale, and deliver the highest quality care to patients.
Princeton Gastroenterology Associates (“PGA”), a regional leader for over 30 years in the treatment of gastrointestinal and liver disorders, recently announced that they had joined New Jersey’s largest gastroenterology group — Allied Digestive Health (“ADH”).
NASHVILLE, Tenn., Jan. 7, 2022 /PRNewswire/ — One GI, a gastroenterology management services organization, has partnered with Digestive Disease Consultants (“DDC”) in the Cleveland, OH market. Headquartered in Nashville, Tennessee, One GI identifies and partners with leading gastroenterology practices that are seeking a strategic alliance to provide capital and management services to help foster growth, drive economies of scale, and deliver the highest quality care to patients.
CAMBRIDGE, MA—OpenBiome is announcing a collaboration with the University of Minnesota’s Microbiota Therapeutics Program to ensure that patients with recurrent C. difficile infections have access to fecal microbiota transplantation (FMT) until an FDA-approved alternative is available.
Historically, inflammatory bowel disease trials report high rates of White patients enrollment. To promote initiatives toward diversifying the enrolled population, we assessed the reporting of race and ethnicity of patients enrolled in pharmaceutical clinical trials for ulcerative colitis.